Clinical study of antibody cocktail therapy for COVID-19
Journal of the Japanese Association for Infectious Diseases
; 96(5):179-185, 2022.
Article
in Japanese
| GIM | ID: covidwho-2203546
ABSTRACT
Background:
Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Prognostic study
Language:
Japanese
Journal:
Journal of the Japanese Association for Infectious Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS